NNVC - NANOVIRICIDES, INC.

1.21
-0.040   -3.306%

Share volume: 451,033
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$1.25
-0.04
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 4%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.97%
1 Month
39.08%
3 Months
21.00%
6 Months
-34.95%
1 Year
-9.70%
2 Year
7.08%
Key data
Stock price
$1.21
P/E Ratio 
0.00
DAY RANGE
$1.13 - $1.28
EPS 
-$0.49
52 WEEK RANGE
$0.85 - $2.23
52 WEEK CHANGE
-$11.68
MARKET CAP 
20.337 M
YIELD 
N/A
SHARES OUTSTANDING 
21.595 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.36
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$306,806
AVERAGE 30 VOLUME 
$246,306
Company detail
CEO: Anil R. Diwan
Region: US
Website: nanoviricides.com
Employees: 20
IPO year: 2005
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NanoViricides, Inc. discovers, develops, and commercializes drugs for the treatment of viral infections. Company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction. Company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide.

Recent news